


GV-58

Chemical Properties

CAS No. : 1402821-41-3
 Formula: C₁₈H₂₆N₆O₅
 Molecular Weight: 374.5
 Appearance: no data available
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	GV-58 is a selective N- and P/Q-type Ca ²⁺ channels agonist (EC ₅₀ : 7.21/8.81 uM for N-type/P-Q-type Ca ²⁺ channel). The inhibitory of GV-58 is 20-fold fewer for CDK kinases activity.
Targets(IC ₅₀)	Calcium Channel
In vitro	In comparison with the parent molecule, (R)-roscovitine, GV-58 has a 20-fold less potent cyclin-dependent kinase antagonist effect, a 3- to 4-fold more potent Ca ²⁺ channel agonist effect, and 4-fold higher efficacy as a Ca ²⁺ channel agonist. GV-58 had no agonist activity (up to 100 μm) on the L-type α-subunit we tested (Cav1.3).

Solubility Information

Solubility	DMSO: 90 mg/mL (240.32 mM),Sonication is recommended. Methanol: 55 mg/mL (146.86 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6702 mL	13.3511 mL	26.7023 mL
5 mM	0.534 mL	2.6702 mL	5.3405 mL
10 mM	0.267 mL	1.3351 mL	2.6702 mL
50 mM	0.0534 mL	0.267 mL	0.534 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Tarr TB, et al. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. J Neurosci. 2013 Jun 19;33(25):10559-67.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481